Lab result explainedInflammationLast updated November 11, 2026

Lupus anticoagulant test: what a positive result means, dRVVT ratios, pregnancy and why it is not lupus

Lupus anticoagulant (LA) · Lupus anticoagulant panel (dRVVT and lupus-sensitive aPTT with mixing and confirm steps), usually ordered with anticardiolipin and anti-beta-2 glycoprotein I antibodies · reported in Normalized ratios for the dRVVT and lupus-sensitive aPTT screen and confirm steps (positive above the lab's cut-off, typically about 1.2), reported overall as positive, negative or indeterminate

A lupus anticoagulant (LA) is an antibody that interferes with the phospholipid-dependent steps of clotting tests in a laboratory tube and, in the body, raises the risk of blood clots rather than bleeding. Both halves of the name mislead. Most people who test positive do not have lupus, and the antibody does not thin the blood. It got the name in the 1950s because it was first noticed in patients with lupus whose plasma took unusually long to clot in the test tube. It is now one of the three laboratory tests for antiphospholipid syndrome (APS), alongside anticardiolipin and anti-beta-2 glycoprotein I antibodies.

The test is a sequence rather than a single number. The laboratory runs two clotting tests built on different principles, usually the dilute Russell viper venom time (dRVVT) and a lupus-sensitive activated partial thromboplastin time (aPTT). If a screen is prolonged, the sample is mixed with normal plasma (a lupus anticoagulant does not correct, whereas a missing clotting factor does) and then retested with an excess of phospholipid, which neutralizes the antibody and shortens the clotting time. A positive report usually means a normalized dRVVT ratio above about 1.2, with the cut-off set by each lab. Because infections, medicines and acute illness can produce a short-lived lupus anticoagulant that means nothing, a positive result is repeated at least 12 weeks later before it is considered real.

A persistent lupus anticoagulant matters because it is the strongest of the antiphospholipid antibodies for predicting clots and pregnancy complications. A systematic review found it raised the odds of thrombosis roughly 5 to 16 fold, far more than anticardiolipin antibodies, and in the PROMISSE pregnancy study 39 percent of women with a lupus anticoagulant had a serious pregnancy complication compared with 3 percent of antibody-positive women without one. Many people first meet the term when a routine pre-operative aPTT comes back unexpectedly long. In that setting a positive result is a risk marker to be confirmed and interpreted, not a diagnosis on its own.

LA at a glance

What it is: an antiphospholipid antibody that prolongs clotting tests in the tube but promotes clotting in the body; the name is historical and it does not mean you have lupus.
Normal: negative, meaning the dRVVT and lupus-sensitive aPTT ratios are at or below the lab's cut-off (about 1.2 at most US labs).
Positive: a prolonged screen that does not correct on mixing with normal plasma and does correct with added phospholipid; it must be found again at least 12 weeks later to count.
Persistently positive with a clot or a qualifying pregnancy complication meets criteria for antiphospholipid syndrome; positive with neither is a carrier state with raised but not certain risk.
False positives come from heparin, warfarin and especially apixaban, rivaroxaban and dabigatran, and from acute infection or inflammation; false negatives occur soon after a clot when factor VIII is high.
Next step: repeat in 12 weeks with anticardiolipin and anti-beta-2 glycoprotein I antibodies; if persistent, your clinician weighs your clot history, pregnancy plans and other risk factors.

Have your whole report? Paste it into the free Lab Explainer

Every marker explained in plain language, in context with the others, with questions to bring to your appointment. No account needed.

What LA measures

Despite the name, the antibodies are not directed at phospholipids themselves but at proteins that bind to them, mainly beta-2 glycoprotein I and prothrombin. In a clotting test the antibody-protein complexes coat the phospholipid surface the clotting enzymes need, so the clot forms more slowly and the time is prolonged. In a blood vessel the same complexes activate endothelial cells, platelets, monocytes and the complement system and interfere with natural anticoagulant proteins such as protein C, which tips the balance toward thrombosis. That is why a test that looks like a bleeding problem signals a clotting problem.

Guidelines from the International Society on Thrombosis and Haemostasis (ISTH) specify the method. Blood is collected in citrate and spun twice to remove platelets, because platelet fragments supply phospholipid and hide the antibody. Two tests with different principles are run, almost always the dRVVT (which activates factor X directly with snake venom) and an aPTT reagent with a low phospholipid content such as a silica clotting time. Each has three steps: screen, mix and confirm. Results are expressed as ratios against normal pooled plasma, and the cut-off for each step is the 99th percentile of at least 120 healthy donors, which is why 1.2 is typical but not universal. A lupus anticoagulant is reported if either test system completes all three steps.

Several things distort the result. Heparin is neutralized by most dRVVT reagents up to about 1 unit/mL but not reliably by aPTT reagents. Warfarin prolongs both screens and can give a false positive or mask a true one; testing is best done when the INR is below 1.5 or interpreted with a 1:1 mix. The direct oral anticoagulants rivaroxaban, apixaban, edoxaban and dabigatran cause false positive dRVVT results in a large share of samples unless the drug is removed with an activated charcoal product or the blood is drawn at trough. A high C-reactive protein can also produce a false positive dRVVT, and the high factor VIII of acute illness or pregnancy can shorten the aPTT and hide a weak antibody. For all these reasons, testing is ideally done when you are well, before anticoagulants start or at least 12 weeks after a clot.

Normal range for LA

Reference ranges vary between labs and by age, sex and pregnancy. Use the range printed on your own report.

Group	Typical range (Normalized ratios for the dRVVT and lupus-sensitive aPTT screen and confirm steps (positive above the lab's cut-off, typically about 1.2), reported overall as positive, negative or indeterminate)	Notes
Negative	dRVVT and lupus-sensitive aPTT screen ratios at or below the lab's cut-off (about 1.2)	No lupus anticoagulant detected. Labs set their own cut-offs at the 99th percentile of healthy donors; some use 1.16 to 1.3.
Prolonged screen only	Screen ratio above the cut-off	Triggers the mixing and confirm steps. On its own it is not a positive result: clotting factor deficiency, heparin, warfarin or a DOAC can all do this.
Mixing step	Mixed 1:1 with normal plasma, the ratio stays above the cut-off (or index of circulating anticoagulant above about 10 to 15 percent)	Failure to correct points to an inhibitor rather than a missing factor. Correction on mixing suggests factor deficiency or a weak antibody diluted out.
Confirm step	Screen-to-confirm normalized ratio above the cut-off (about 1.2), or more than about 10 percent shortening with excess phospholipid	Shortening with added phospholipid shows the inhibitor is phospholipid-dependent, which is what defines a lupus anticoagulant.
Positive (single occasion)	All three steps met in the dRVVT or the aPTT system	Reported as positive or 'lupus anticoagulant detected'. Needs repeating after at least 12 weeks; a sizable minority of first positives are transient.
Indeterminate	Prolonged screen with incomplete criteria, or a sample taken on an anticoagulant	Common with DOACs and warfarin. Repeat off anticoagulation if safe, at trough, or after charcoal adsorption of the drug.
Persistently positive	Positive on two or more occasions at least 12 weeks apart	Satisfies the laboratory requirement for antiphospholipid syndrome. Diagnosis still needs a clinical event (thrombosis or a qualifying pregnancy complication).
Triple positive	Lupus anticoagulant plus anticardiolipin plus anti-beta-2 glycoprotein I antibodies	The highest-risk profile. In carriers with no prior event, a first thrombosis occurred at about 5 percent a year and 37 percent over 10 years in a prospective cohort.

Positive lupus anticoagulant

A single positive lupus anticoagulant says that, on the day of the test, something in your plasma behaved like a phospholipid-dependent inhibitor. Broadly, that is one of three things: a genuine, persistent antiphospholipid antibody; a temporary antibody produced during an infection, an acute illness or while taking certain drugs; or an artifact of an anticoagulant or a poorly prepared sample. The 12-week repeat sorts the first from the other two, which is why no diagnosis is made on one result.

A persistently positive lupus anticoagulant means your clotting risk is higher than average, but how much higher depends on context. In people who have already had a clot it is the laboratory finding most strongly linked to another one, and it is the main reason long-term warfarin rather than a short course is recommended for unprovoked thrombosis in antiphospholipid syndrome. In someone who has never had a clot the absolute risk is lower: roughly 1 to 2 percent a year for an isolated lupus anticoagulant, rising to about 5 percent a year with triple positivity, and higher again with smoking, estrogen-containing contraception, surgery, immobility or active lupus.

In pregnancy a lupus anticoagulant is the single best laboratory predictor of trouble. It is associated with recurrent early miscarriage, fetal death after 10 weeks, early severe preeclampsia and placental insufficiency with growth restriction. With low-dose aspirin and prophylactic heparin, live birth rates in women with obstetric antiphospholipid syndrome reach about 70 to 80 percent in trials and cohorts, which is why the result changes antenatal care rather than being a reason to avoid pregnancy.

Common causes

Primary antiphospholipid syndrome
An autoimmune condition in which antiphospholipid antibodies cause clots or pregnancy complications without another autoimmune disease. About half of people with APS have the primary form; a lupus anticoagulant is present in roughly half to two thirds of them.
Systemic lupus erythematosus and other autoimmune diseases
About 30 to 40 percent of people with lupus have antiphospholipid antibodies and 15 to 30 percent have a lupus anticoagulant; a third or so of these go on to develop APS. It also occurs in rheumatoid arthritis, Sjögren's syndrome, systemic sclerosis and immune thrombocytopenia.
Infections
HIV, hepatitis C, Epstein-Barr virus, parvovirus B19, syphilis, Lyme disease, COVID-19 and some bacterial infections can induce a transient lupus anticoagulant, especially in children, where it is often found after a viral illness when a pre-operative aPTT is long. These usually clear within 3 months and rarely cause clots.
Medications
Chlorpromazine, procainamide, hydralazine, quinidine, phenytoin, interferon alfa and TNF inhibitors can all induce a lupus anticoagulant. Drug-induced antibodies are usually low risk and fade over months after the drug is stopped.
Anticoagulants interfering with the test
Rivaroxaban, apixaban, edoxaban and dabigatran produce false positive dRVVT results in a large share of samples; warfarin and high-dose heparin can also do so. This is a laboratory artifact, not a true antibody, and the usual reason for an 'indeterminate' report.
Acute inflammation and recent thrombosis
A very high C-reactive protein can bind phospholipid in the test and mimic a lupus anticoagulant, while the high factor VIII of acute illness can hide one. Testing in the days after a clot or during a severe infection is unreliable in both directions.
Cancer
Lymphoma, leukemia and some solid tumors are associated with antiphospholipid antibodies, including a lupus anticoagulant, and with a higher clot risk. In an older adult with a new positive result and no other explanation, this is part of the differential.
Healthy people
Low-level antiphospholipid antibodies are found in 1 to 5 percent of healthy adults and a lupus anticoagulant in perhaps 1 percent, more often with age. Most are transient or low risk, which is why persistence and the full antibody profile matter.

Symptoms that can go with it

Often none; the result is commonly found when a pre-operative aPTT is unexpectedly long
Deep vein thrombosis (a painful swollen calf) or pulmonary embolism (sudden breathlessness, chest pain, coughing blood)
Stroke or transient ischemic attack, particularly in someone under 50
Recurrent early miscarriage, a loss after 10 weeks, early severe preeclampsia or a growth-restricted baby
Livedo reticularis, a lace-like purple mottling of the skin on the legs or arms
Low platelets with easy bruising; the drop is usually mild (70,000 to 120,000 per microliter)
Heart valve thickening or murmurs, migraine-like headaches, memory or concentration problems

Read it alongside

aPTT (partial thromboplastin time) — an unexplained prolonged aPTT that does not correct on mixing is the classic clue; a normal aPTT does not exclude a lupus anticoagulant because many reagents are insensitive to it.
Anticardiolipin and anti-beta-2 glycoprotein I antibodies — the other two criteria tests; triple positivity carries the highest risk and all three should be drawn together.
PT/INR — some lupus anticoagulants prolong the prothrombin time and make the INR unreliable for warfarin dosing, so the lab may need a chromogenic factor X assay instead.
Platelet count — mild thrombocytopenia accompanies antiphospholipid antibodies in 20 to 40 percent of people with APS and does not protect against clotting.
D-dimer — raised when a clot is forming or dissolving; used with imaging to investigate suspected DVT or PE, not to diagnose APS.
ANA and anti-dsDNA — a positive lupus anticoagulant prompts a check for underlying lupus, which changes management.
Complement C3 and C4 — low levels suggest active lupus or, in pregnancy, a higher risk of complications in antibody-positive women.
RPR (syphilis screen) — antiphospholipid antibodies cause a biological false positive syphilis test, which is sometimes how they are first noticed.

What usually happens next

Confirm the result: a positive lupus anticoagulant is repeated at least 12 weeks later, ideally with anticardiolipin and anti-beta-2 glycoprotein I antibodies on both occasions, when you are well and, if it is safe, not on an anticoagulant.
Tell the lab and your clinician about every blood thinner, including heparin injections, warfarin and the direct oral anticoagulants, and about any recent infection or clot, since all of these can produce a false positive or negative.
Expect a review of your history for past clots, miscarriages, preeclampsia, migraines, livedo and symptoms of lupus, with a CBC, ANA, anti-dsDNA and complement if lupus has not already been excluded.
If the antibody is persistent and you have had a clot, the discussion is about long-term anticoagulation, usually warfarin; if you have never had a clot, it is about your overall risk profile, low-dose aspirin, avoiding estrogen-containing contraception and clot prevention around surgery, travel and pregnancy.
If you are pregnant or planning pregnancy, ask for referral to a maternal-fetal medicine or obstetric medicine clinic, since treatment with aspirin and heparin changes outcomes and is best started early.

Diet, lifestyle and natural levers with evidence

What can move LA once the cause is known. Nothing here replaces finding the cause.

Nothing natural changes a lupus anticoagulant

Strong evidence

No diet, herb or supplement has been shown in human studies to make a persistent lupus anticoagulant disappear or to lower its strength. The antibody tends to persist for years, and management rests on reducing clot risk rather than on changing the test. The levers below affect what the result means and how much risk it carries, not the result itself.

Timing the test around anticoagulants, infections and clots

Strong evidence

Direct oral anticoagulants falsely prolong the dRVVT in most samples taken at peak drug level; drawing blood at trough (just before the next dose) or having the lab remove the drug with an activated charcoal product restores accuracy. Warfarin is best handled by testing when the INR is below 1.5 or by relying on the mixing step, and testing is deferred for about 12 weeks after a clot or a significant infection. Getting the timing right prevents both false reassurance and an unnecessary lifelong label.

Stop smoking and avoid estrogen-containing contraception or hormone therapy

Strong evidence

In the RATIO case-control study, young women with a lupus anticoagulant had about 40 times the risk of ischemic stroke of women without one, and the risk was far higher again in those who also used estrogen-containing oral contraceptives or smoked. EULAR recommends that women with antiphospholipid antibodies avoid estrogen-containing contraception in favor of progestin-only or non-hormonal methods, and that all carriers stop smoking and manage blood pressure, cholesterol and weight.

Do not stop a prescribed contraceptive or hormone therapy without arranging an alternative; discuss the switch with your clinician.

Clot-prevention habits during high-risk periods

Moderate evidence

Immobility, long-haul travel, surgery, hospital admission and the weeks after childbirth are when carriers most often have a first clot. Walking regularly on flights, staying hydrated, early mobilization after surgery and asking for pharmacological prophylaxis (usually low-molecular-weight heparin) around operations and after delivery are standard advice in APS guidelines. Regular physical activity and a healthy weight lower baseline venous thrombosis risk by roughly a third in population studies.

Vitamin D if you are deficient

Preliminary evidence

Vitamin D deficiency is more common in antiphospholipid syndrome (about 50 percent versus 30 percent of controls in one series) and is associated with thrombotic rather than purely obstetric disease; in laboratory studies vitamin D reduces the tissue factor expression triggered by antiphospholipid antibodies. No trial has shown that correcting deficiency prevents clots or changes the lupus anticoagulant, so this is a reason to check and replace a low level, not a treatment.

Avoid high-dose vitamin D without a measured level, particularly if you have kidney stones, high calcium or sarcoidosis.

When to see a clinician promptly

Emergency: a painful swollen leg, sudden breathlessness, chest pain or coughing blood, which may be deep vein thrombosis or pulmonary embolism.
Emergency: face drooping, arm weakness, slurred speech, sudden loss of vision or the worst headache of your life, which may be a stroke.
In pregnancy: severe headache, visual disturbance, pain under the right ribs, sudden swelling of the face and hands or reduced fetal movements, which can signal preeclampsia or placental problems and need same-day assessment.
Rapidly spreading rash, confusion, falling urine output or breathlessness over hours to days in someone known to be positive, which can be catastrophic antiphospholipid syndrome, a rare emergency in which several organs clot at once.
Unusual bruising, nosebleeds or bleeding gums, since a low platelet count (and rarely a low prothrombin level) can accompany a lupus anticoagulant and must be assessed before any anticoagulant is started.
Before any surgery, hormone treatment, long-haul travel or a planned pregnancy, so that clot prevention can be arranged.

Frequently asked questions

Does a positive lupus anticoagulant mean I have lupus?

No. The name is historical. Only a minority of people with a lupus anticoagulant have systemic lupus erythematosus; most have primary antiphospholipid syndrome, a transient antibody after an infection or a drug, or an isolated antibody with no disease. Because the two do travel together, a positive result is usually followed by an ANA, anti-dsDNA and complement test to check for lupus, and about 30 to 40 percent of people with lupus carry an antiphospholipid antibody.

What is a normal lupus anticoagulant result?

Normal is 'negative' or 'not detected', which means the dRVVT and lupus-sensitive aPTT ratios were at or below the lab's cut-off, typically about 1.2 against normal plasma, or a prolonged screen corrected with mixing or failed the confirm step. There is no 'low' lupus anticoagulant; it is either present or not. Some reports show the individual ratios, and a value a fraction above the cut-off in one system is less convincing than clear positivity in both.

Can a lupus anticoagulant go away?

Yes. Antibodies that appear during an infection, with certain drugs or in children after a viral illness usually disappear within 3 months, which is the reason for the 12-week repeat. Persistent antibodies tend to stay for years, although their strength fluctuates and a minority of people become negative over time. A result that is negative on repeat and was positive only once is generally regarded as transient, provided the first sample was not taken on an anticoagulant.

What happens if I have a lupus anticoagulant and I am pregnant?

You will usually be referred to a specialist antenatal clinic. If you have had previous qualifying losses or a clot, the standard treatment is low-dose aspirin plus prophylactic low-molecular-weight heparin through pregnancy and for 6 weeks after delivery; Cochrane reviews find this roughly halves the rate of pregnancy loss, and live birth rates of 70 to 80 percent are typical. If the antibody was found incidentally with no previous problems, aspirin alone and closer monitoring of blood pressure and fetal growth are common. Warfarin is avoided in pregnancy because it harms the fetus.

Why is my aPTT long if I am at risk of clots, not bleeding?

The antibody blocks the phospholipid surface that the test's enzymes need, so clotting in the tube is slow. In your blood vessels there is plenty of phospholipid on cell membranes, and the same antibody activates platelets and the vessel lining and interferes with natural anticoagulants, so the net effect is clotting. A lupus anticoagulant does not cause bleeding unless it is combined with very low platelets or, rarely, with antibodies that remove prothrombin from the blood.

Can I take birth control pills with a lupus anticoagulant?

Estrogen-containing pills, patches and rings are not recommended because they multiply the already raised clot and stroke risk; in young women with a lupus anticoagulant who also used combined oral contraceptives, stroke risk in the RATIO study was more than 100 times that of unexposed women. Progestin-only methods (the mini-pill, implant, hormonal IUD or injection) and copper IUDs are considered safe. The same applies to estrogen-containing hormone therapy at menopause.

Do I need blood thinners if I have never had a clot?

Not automatically. Long-term anticoagulation is reserved for people who have had a clot. For carriers without a clot, EULAR suggests low-dose aspirin (75 to 100 mg) when the antibody profile is high risk (a lupus anticoagulant, especially with triple positivity) or lupus is present; a meta-analysis of observational studies found aspirin was associated with about half the rate of a first clot in antibody carriers, although the one randomized trial was too small to confirm it. Short-term heparin around surgery, immobility and childbirth is standard.

What is the difference between lupus anticoagulant and anticardiolipin antibodies?

They are two ways of detecting overlapping antibodies. Anticardiolipin and anti-beta-2 glycoprotein I tests measure antibody binding directly and are reported in units; the lupus anticoagulant test measures the antibody's effect on clotting in the tube and is reported as positive or negative. A person can be positive on any combination. The lupus anticoagulant correlates most strongly with clots and pregnancy loss, isolated low-titer anticardiolipin IgM least, and positivity on all three carries the highest risk.

References

Antiphospholipid antibodies. MedlinePlus, US National Library of Medicine (2023)
Devreese KMJ, de Groot PG, de Laat B, et al.. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. Journal of Thrombosis and Haemostasis (2020)
Miyakis S, Lockshin MD, Atsumi T, et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis (2006)
Barbhaiya M, Zuily S, Naden R, et al.. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis & Rheumatology (2023)
Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood (2003)
Pengo V, Ruffatti A, Legnani C, et al.. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood (2011)
Lockshin MD, Kim M, Laskin CA, et al.. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis & Rheumatism (2012)
Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurology (2009)
Tektonidou MG, Andreoli L, Limper M, et al.. EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases (2019)
Hamulyák EN, Scheres LJ, Marijnen MC, Goddijn M, Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database of Systematic Reviews (2020)
Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. New England Journal of Medicine (2018)
Antiphospholipid antibody syndrome (APS). Merck Manual Professional Version (2024)

Related markers

Related conditions

Evidence guides

Worried about your number?

Ask AskMN what your LA result could mean in the context of your other results, symptoms and medications. Free, unlimited, no account needed.

Ask about my LA

This page is educational and is not medical advice or a diagnosis. Lab results have to be interpreted together with your history, symptoms and other results by a clinician who knows you. Do not start or stop a supplement to change a lab value before the cause is known.